+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Intravenous Immunoglobulin Market by End User (Home Care, Hospital, Specialty Clinic), Product Type (High Purity Immunoglobulin, Normal Immunoglobulin), Patient Type, Distribution Channel, Indication - Global Forecast 2025-2030- Product Image
Intravenous Immunoglobulin Market by End User (Home Care, Hospital, Specialty Clinic), Product Type (High Purity Immunoglobulin, Normal Immunoglobulin), Patient Type, Distribution Channel, Indication - Global Forecast 2025-2030- Product Image
Sale

Intravenous Immunoglobulin Market by End User (Home Care, Hospital, Specialty Clinic), Product Type (High Purity Immunoglobulin, Normal Immunoglobulin), Patient Type, Distribution Channel, Indication - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 191 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5889544
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

In the healthcare sector, the intravenous immunoglobulin market is evolving rapidly, driven by clinical adoption, supply chain recalibration, and continuous innovation. Senior decision-makers operating in pharmaceuticals, healthcare provision, or biotechnology face dynamic shifts in therapeutic demand, regulatory frameworks, and operational resilience as the landscape grows more complex and competitive.

Market Snapshot: Intravenous Immunoglobulin Market Growth and Competitive Landscape

The intravenous immunoglobulin market grew from USD 1.33 billion in 2024 to USD 1.43 billion in 2025. With a projected CAGR of 6.94%, the sector is set to reach USD 2.00 billion by 2030, signifying robust demand and strategic opportunity for both incumbent leaders and emerging entrants. Therapeutic use continues expanding across immunology, neurology, and hematology. Global shifts in regulatory policy, health system reforms, and reimbursement models are actively reshaping value chain configurations and competitive dynamics.

Scope & Segmentation: Unlocking Opportunity Across Stakeholder Groups

  • End User Settings: Home care, hospital (private and public), and specialty clinics (hematology, immunology, neurology) deliver intravenous immunoglobulin through tailored patient engagement models and care protocols.
  • Product Types: High purity immunoglobulin formulations address critical safety margins; normal immunoglobulin is available in both liquid and lyophilized formats.
  • Patient Categories: Adults comprise the largest recipient group for chronic therapies, while geriatric and pediatric populations benefit from dose customization and stringent safety oversight.
  • Distribution Channels: Pathways include direct sales to hospital systems, hospital and retail pharmacies, and wholesale distributors that support smaller medical practices.
  • Therapeutic Indications: Treatment areas encompass autoimmune diseases (such as Guillain-Barré syndrome, immune thrombocytopenic purpura, Kawasaki disease), hematological conditions (e.g., newborn hemolytic disorders), immunodeficiency (primary and secondary), and neurological disorders (including chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy).
  • Geographic Regions: Strategic regions include the Americas, Europe, Middle East & Africa, and Asia-Pacific, with targeted markets such as the United States, China, Japan, Germany, and Brazil.
  • Industry Players: CSL Limited, Grifols S.A., Takeda Pharmaceutical Company, Octapharma AG, Baxter International, Biotest AG, Bio Products Laboratory, Kedrion S.p.A., LFB S.A., and Shanghai RAAS Blood Products.

Key Takeaways: Strategic Insights for Decision-Makers

  • Therapeutic innovation, such as subcutaneous and high-purity intravenous immunoglobulin, is shifting administration protocols and raising standards for efficacy and safety.
  • Advanced supply chain strategies now emphasize collaboration with specialty pharmacies and modular manufacturing to enhance agility and product availability.
  • Health policy reforms and value-based reimbursement models are driving manufacturers to reassess risk-sharing agreements and align cost structures with clinical outcomes.
  • Greater transparency and engagement with regulatory agencies are accelerating product approvals, benefiting both originator and biosimilar entrants.
  • Digital health platforms for infusion monitoring and remote adherence tracking are enhancing patient outcomes and improving real-world data collection.
  • Geographic segmentation is critical with market maturity varying by region, requiring tailored commercial and distribution strategies to ensure equitable access and regional compliance.

Tariff Impact: Navigating U.S. Trade Policy Consequences

The 2025 implementation of United States tariffs on plasma derivatives has driven landed costs upward for import-reliant providers and refocused attention on domestic manufacturing. Organizations have diversified plasma sourcing and formed public-private alliances to bolster capacity, while also navigating evolving trade agreements to safeguard patient access and manage pricing negotiations. Dynamic tariff modeling is now integral to procurement and contracting frameworks.

Methodology & Data Sources

This report applies multi-source data collection, merging secondary research from peer-reviewed journals and industry databases with interviews of key opinion leaders and executives from top biopharma firms. Structured surveys and advanced analytics—including scenario modeling and sensitivity testing—strengthen insight robustness, with findings validated through expert panel reviews.

Why This Report Matters: Actionable Value for Leadership

  • Enables executive teams to calibrate investment, operational, and market access strategies in alignment with evolving clinical and policy trends within the intravenous immunoglobulin arena.
  • Supports informed decision-making with in-depth coverage of segmentation, innovation, regional dynamics, and competitive activities for precise opportunity targeting.
  • Delivers clarity on regulatory, supply chain, and reimbursement complexities, empowering senior stakeholders to future-proof business models and sustain patient-centric care delivery.

Conclusion

The intravenous immunoglobulin market demands strategic foresight and operational adaptability from industry leaders. This report offers the context and analysis required to secure competitive advantage, drive innovation, and ensure resilient patient care in a changing therapeutic landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Impact of biosimilar immunoglobulin launches on pricing and adoption of standard IVIG therapies
5.2. Integration of personalized dosing algorithms to optimize IVIG treatment efficiency and outcomes
5.3. Growing use of intravenous immunoglobulin in autoimmune neurology and rare disease therapies landscape
5.4. Supply chain diversification strategies to mitigate raw plasma shortages and ensure IVIG availability
5.5. Regulatory harmonization initiatives accelerating approval of next generation IVIG formulations globally
5.6. Technological advancements in fractionation processes driving higher purity and safety of IVIG products
5.7. Increasing off-label use of IVIG in dermatological conditions driving new clinical safety studies
5.8. Shifts towards home-based IVIG administration models enhancing patient convenience and healthcare cost efficiencies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Intravenous Immunoglobulin Market, by End User
8.1. Introduction
8.2. Home Care
8.3. Hospital
8.3.1. Private Hospital
8.3.2. Public Hospital
8.4. Specialty Clinic
8.4.1. Hematology Clinic
8.4.2. Immunology Clinic
8.4.3. Neurology Clinic
9. Intravenous Immunoglobulin Market, by Product Type
9.1. Introduction
9.2. High Purity Immunoglobulin
9.3. Normal Immunoglobulin
9.3.1. Liquid
9.3.2. Lyophilized
10. Intravenous Immunoglobulin Market, by Patient Type
10.1. Introduction
10.2. Adult
10.3. Geriatric
10.4. Pediatric
11. Intravenous Immunoglobulin Market, by Distribution Channel
11.1. Introduction
11.2. Direct Sales
11.3. Hospital Pharmacy
11.4. Retail Pharmacy
11.5. Wholesale Distributor
12. Intravenous Immunoglobulin Market, by Indication
12.1. Introduction
12.2. Autoimmune Diseases
12.2.1. Guillain-Barré Syndrome
12.2.2. Immune Thrombocytopenic Purpura
12.2.3. Kawasaki Disease
12.3. Hematological Conditions
12.3.1. Hemolytic Disease Of The Newborn
12.4. Immunodeficiency Disorders
12.4.1. Primary Immunodeficiency
12.4.2. Secondary Immunodeficiency
12.5. Neurological Disorders
12.5.1. Chronic Inflammatory Demyelinating Polyneuropathy
12.5.2. Multifocal Motor Neuropathy
13. Americas Intravenous Immunoglobulin Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Intravenous Immunoglobulin Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Intravenous Immunoglobulin Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. CSL Limited
16.3.2. Grifols, S.A.
16.3.3. Takeda Pharmaceutical Company Limited
16.3.4. Octapharma AG
16.3.5. Baxter International Inc.
16.3.6. Biotest AG
16.3.7. Bio Products Laboratory Limited
16.3.8. Kedrion S.p.A.
16.3.9. LFB S.A.
16.3.10. Shanghai RAAS Blood Products Co., Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. INTRAVENOUS IMMUNOGLOBULIN MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. INTRAVENOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. INTRAVENOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. INTRAVENOUS IMMUNOGLOBULIN MARKET: RESEARCHAI
FIGURE 26. INTRAVENOUS IMMUNOGLOBULIN MARKET: RESEARCHSTATISTICS
FIGURE 27. INTRAVENOUS IMMUNOGLOBULIN MARKET: RESEARCHCONTACTS
FIGURE 28. INTRAVENOUS IMMUNOGLOBULIN MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. INTRAVENOUS IMMUNOGLOBULIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNOLOGY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNOLOGY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HIGH PURITY IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HIGH PURITY IMMUNOGLOBULIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY WHOLESALE DISTRIBUTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY WHOLESALE DISTRIBUTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GUILLAIN-BARRÉ SYNDROME, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GUILLAIN-BARRÉ SYNDROME, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNE THROMBOCYTOPENIC PURPURA, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNE THROMBOCYTOPENIC PURPURA, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY KAWASAKI DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY KAWASAKI DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMOLYTIC DISEASE OF THE NEWBORN, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMOLYTIC DISEASE OF THE NEWBORN, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 147. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 150. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 151. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2024 (USD MILLION)
TABLE 152. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2025-2030 (USD MILLION)
TABLE 153. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 154. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 155. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
TABLE 156. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2025-2030 (USD MILLION)
TABLE 157. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 158. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 159. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
TABLE 164. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2030 (USD MILLION)
TABLE 165. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2024 (USD MILLION)
TABLE 166. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2025-2030 (USD MILLION)
TABLE 167. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2024 (USD MILLION)
TABLE 168. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2025-2030 (USD MILLION)
TABLE 169. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 170. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 171. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 174. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 175. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2024 (USD MILLION)
TABLE 176. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2025-2030 (USD MILLION)
TABLE 177. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 178. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 179. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
TABLE 180. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2025-2030 (USD MILLION)
TABLE 181. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 182. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 183. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 186. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 187. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
TABLE 188. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2030 (USD MILLION)
TABLE 189. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2024 (USD MILLION)
TABLE 190. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2025-2030 (USD MILLION)
TABLE 191. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2024 (USD MILLION)
TABLE 192. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2025-2030 (USD MILLION)
TABLE 193. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 194. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 272. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2024 (USD MILLION)
TABLE 274. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2025-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 276. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
TABLE 278. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2025-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 280. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 282. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 284. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
TABLE 286. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2024 (USD MILLION)
TABLE 288. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2025-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2024 (USD MILLION)
TABLE 290. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 293. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 294. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 295. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 296. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 297. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2024 (USD MILLION)
TABLE 298. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2025-2030 (USD MILLION)
TABLE 299. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 300. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 301. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
TABLE 302. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOG

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Intravenous Immunoglobulin market report include:
  • CSL Limited
  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Baxter International Inc.
  • Biotest AG
  • Bio Products Laboratory Limited
  • Kedrion S.p.A.
  • LFB S.A.
  • Shanghai RAAS Blood Products Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages191
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.43 Billion
Forecasted Market Value ( USD ) by 2030 $ 2 Billion
Compound Annual Growth Rate6.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Immunodeficiency Diseases), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Immunodeficiency Diseases), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 153 Pages
  • Global
From
Intravenous Immunoglobulin Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025-2033 - Product Image

Intravenous Immunoglobulin Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025-2033

  • Report
  • 175 Pages
  • Global
From
Intravenous Immunoglobulin Market Report 2025 - Product Image

Intravenous Immunoglobulin Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Intravenous Immunoglobulin (IVIG) Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Application - Product Image

Intravenous Immunoglobulin (IVIG) Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Application

  • Report
  • 94 Pages
  • Global
From
Intravenous Immunoglobulin Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Intravenous Immunoglobulin Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From

About the Intravenous Immunoglobulin Market

The Intravenous Immunoglobulin (IVIG) market is a subset of the biotechnology industry that focuses on the production and distribution of immunoglobulin products. IVIG is a blood product derived from the pooled plasma of healthy donors, and is used to treat a variety of conditions, including autoimmune diseases, infections, and immunodeficiencies. IVIG is also used in the prevention of certain infections in immunocompromised patients. IVIG is produced by a number of companies, including CSL Behring, Grifols, Kedrion, Octapharma, and Biotest. These companies are involved in the production, distribution, and marketing of IVIG products. They also provide support services such as patient education, reimbursement assistance, and clinical trial support. Additionally, some companies are involved in the development of new IVIG products, such as recombinant immunoglobulins and monoclonal antibodies. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.